Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis

January 29, 2019

View Press Release Corporate presentation Contact us
Previous